Home >> Journals >> JMS
About JMS
Home
Indexing
Aims and Scope
Article Archives
Editorial Board
Author guidelines
Recommendation
Recommend to Peers
Recommend to Library
Sales
Subscription
Most popular papers
pic

Journal of Medical Science

ISSN 2327-0276 (Print)

ISSN 2327-0284 (Online)

Website: http://www.researchpub.org/journal/jms/jms.html

Volume 01, Number 01  (2013)
Effects of Detraining on Physical Fitness and Cardiovascular Variables in Non-institutionalized Elders
Author(s) Lobo, A
Abstract

The purpose of the present study was to investigate the effects of 2-month detraining on physical fitness and cardiovascular health variables.
37 non-institutionalized elders, which completed 1-year of a multicomponental physical activity program, were reevaluated after a 2-month post-intervention for the detraining period. Habitual physical activity (Baecke questionnaire), physical fitness (Functional Fitness Test), body composition (BMI and waist measure), blood pressure, plasma lipid and glucose concentrations were assessed.
Data demonstrated that detraining significantly affected lower body components and the agility/dynamic balance, while there were significant changes in the cardiovascular variables. Our results indicate that favorable physical activity adaptations were lost within 2-months of detraining. Therefore, elders should follow a long-term and systematic exercise routine throughout life, in order to improve and maintain their physical functions and to ameliorate their cardiovascular condition.



References
[1] WHO. World Health Organization. Steps to health A European framework to promote physical activity for health. 2007; http://www.euro.who.int/Document/E90191.pdf.
[2] Spirduso W. Physical dimensions of ageing (Vol. 31). 2005; Champaign, Illinois.
[3] Capodaglio P, Capodaglio EM, Ferri A, et al. Muscle function and functional ability improves more in community-dwelling older women with a mixed-strength training programme. Age Ageing; 2005; 34(2): 141-7.
[4] Henwood TR, Traffe DR. Short-term resistance training and the older adult: the effect of varied programmes for the enhancement of muscle strength and functional performance. Clin Physiol Funct Imagin; 2006; 26(5): 305-13.
[5] ACSM, AHA. Physical Activity and Public Health in older adults: Recommendation from the American College of Sports Medicine and American Heart Association. Geriatric Nursing; 2007; 28 (6): 330-340.
[6] Peterson J, Lowe J, Peterson A, Janz K. The relationship between active living and health-related quality of life: income as a moderator. Health Education Research; 2006; 21(1): 146-156.
[7] Toraman N. Short term and long term detraining: Is there any difference between young-old and old people? Br J Sports Med; 2005; 39: 561-564.
[8] Teixeira-Salmela, Santiago L, Lima R, et al. Functional performance and quality of life related to training and detraining of community-dwelling elderly. Disabil Rehabil; 2005; 27: 1007-1012.
[9] Paffenbarger R. Physical exercise to reduce cardiovascular disease risk. Proceedings of the Nutrition Society; 2000; 59: 4211-4422.
[10] Wessel T, Arant C, Olson M. Relationship of physical fitness vs body mass index with coronary artery disease and cardiovascular events in women. JAMA; 2004; 292: 2232-2234.
[11] Braith R, Stewart K. Resistance Exercise Training: Its Role in the Prevention of Cardiovascular Disease. Braith and Stewart Circulation; 2006; 13: 2642-2650.
[12] Fatouros IG, Kambas A, Katrabasas I, et al. Strength training and detraining effects on muscular strength anaerobic power, and mobility of inactive older men are intensity dependent. Br J Sports Med; 2005; 39: 776-80.
[13] Folstein M, Folstein S, McHugh P. Mini-Mental state a practical Method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research; 1975; 12: 189-198.
[14] Oliveira, M., Maia, J. (2001). Avaliação da actividade física em contextos epidemiológicos. Uma revisão da validade e fiabilidade do acelerómetro Tritrac–R3D, do pedómetro Yamax Digi-Walker e do questionário de Baecke. Revista Portuguesa de Ciências do Desporto, 1(3): 73–88.
[15] Rikli, R., Jones, C. (1999a). Development and validation of a functional fitness test for community-residing older adults. Journal of Aging and Physical Activity, 7(2): 129-161.
[16] Williams, RR., Hopkins, PN., Wu, LL., et al. (1996). Evaluación de los antecedentes familiares para prevenir la cardiopatias coronaria precoz. American Heart Association- Primer de Cardiologia preventive. Barcelona, 301-339.
[17] Forrest KZ, Zmuda JM, Cauley JA. Correlates of decline in lower extremity performance in older women: a 10-year follow-up study. Journals of Gerontology Series A: Biological Sciences and Medical Sciences; 2006; 61A(11): 1194-1200.
[18] Holland G, Tanaka K, Shigematsu R, et al. Flexibility and Physical Functions of Older Adults: A Review. JAP; 2002: 10(2): 169-206.
[19] Misic M, Rosengren K, Woods J, Evans E. Muscle quality, Aerobic fitness and fat mass predict Lower-extremity physical function in community-dwelling older adults. Gerontology; 2007; 53(5), 260-266.
[20] Michelin E, Coelho C, Burini R. Effects of one month detraining over health-related physical fitness in a life style change program. Rev Bras Medicine Esporte; 2008; 14(3): 192-6.
[21] Carvalho J, Marques E, Mota J. Training and detraining effects on functional fitness after a multicomponent training in older women. Gerontology 2009; 55: 41-48.
[22] Fatouros IG, Kambas A, Katrabasas I, et al. Resistance training and detraining effects on flexibility performance in the elderly are intensity-dependent. J Strength and Conditioning Research; 2006; 20(3): 634-42.
[23] Toraman N, Ayceman N. Effects of six weeks of detraining on retention of functional fitness of old people after nine weeks of multicomponent training. Br J Sports Med; 2005; 39(8): 565-8.
[24] Harris C, DeBeliso M, Adams KJ, et al. Detraining in the older adult: effects of prior training intensity on strength retention. J Strength and Conditioning Research; 2007; 21(3): 813-8.
[25] Henwood TR, Traffe DR. Detraining and retraining in older adults following long-term muscle power or muscle strength specific training. J Geront: Med Sci; 2008; 63A(7): 751-8.
[26] Hunter GR, Wetzstein CJ, McLafferty CL, et al. High-resistance versus variable-resistance training in older adults. Med Sci Sports Exerc; 2010; 33(10):1759-64.
[27] Tikhonoff V, Casiglia E, Mazza A. Low-Density Lipoprotein Cholesterol and Mortality in Older People. J Am Geriatr Soc; 2005; 53(12).
[28] Halverstadt A, Phares DA, Wilund KR, et al. Endurance exercise training raises high-density lipoprotein cholesterol and lowers small low-density lipoprotein and very low-density lipoprotein independent of body fat phenotypes in older men and women. Metabolism; 2007; 56(4): 444-50.
[29] Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation; 2007; 115(5): 69-171.
[30] Nelson N, Rejeski W, Blair S. Physical Activity and Public Health in Older Adults: Recommendation from the American College of Sports Medicine and the American Heart Association. Medicine & Science in Sports & Exercise; 2007; 1435-1445.
Hyperlipidemia Aggravates Renal Disease in Bacteremic Male Albino Rats
Author(s) Manar E Selim, Olfat M Yousef, Sherifa H Hamid and Nadia A Aleisa
Abstract

Electron microscopic study is very essential in assessing the nature and state of the tissues. It is used widely to examine the visceral organs in various diseases, infections and disorders. It provides the required insight and details about the possible malfunctioning of the disease or infection. Male adult albino rats with hyperlipidaemia were taken and test group was infected with Escherichia coli.
Abnormalities in lipid metabolism appear to play a pathogenic role in progressive renal disease. The control group was not infected with any clinical pathogen. The electron microscopic examination was carried out to determine the effect of infection in the experimental groups. kidney was the visceral organ which was used for the study. Difference in case of infected male rats when compared with control group rats on the level of electron microscope can be further extended in the case of other clinical pathogenic infections which could lead to interesting results. Hyperlipidemic- bacteremic group showed increased chronic damage in renal tissue. The deleterious effects of hyperlipidemia with its pathogenetic mechanisms, however, leading to an increase in inflammatory mediators in lipid-induced tubulointerstitial degeneration and the relationship between glomerular and tubulointerstitial damage in this case have not been examined before by the electron microscope. The present study was conducted to find out the role of hyperlipidemia and inflammation caused by E coli in the alteration of kidney tissue by the electron microscope in male albino rats.



References
[1] Go AS Chertow, GM, D Fan, CE McCulloch, CY Hsu: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med ,vol.351pp .1296– 1305,2004 CrossRefMedline
[2] MG. Shlipak, R. Katz, MJ. Sarnak, LF. Fried, AB. Newman, C .Stehman-Breen, SL. Seliger, B. Kestenbaum, B. Psaty, RP. Tracy, DS. Siscovick: Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med ,vol.145 pp. 237– 246,2006 Abstract/FREE Full Text
[3] E. Ritz, C. Wanner: Lipid changes and statins in chronic renal insufficiency. J Am Soc Nephro,vol. l17[Suppl]pp. S226– S230,2006 Abstract/FREE Full Text
[4] ND. Vaziri: Dyslipidemia of chronic renal failure: The nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol,vol.290pp. F262– F272,2006 Abstract/FREE Full Text
[5] MG. Shlipak, LF. Fried, M. Cushman, TA. Manolio, D. Peterson, C. Stehman-Breen, A. Bleyer, A. Newman, D. Siscovick, B. Psaty: Cardiovascular mortality risk in chronic kidney disease: Comparison of traditional and novel risk factors. JAMA ,vol.293 pp.1737– 1745,2005Abstract/FREE Full Text
[6] NI. Parikh, SJ .Hwang, MG. Larson, JB. Meigs, D. Levy, CS .Fox: Cardiovascular disease risk factors in chronic kidney disease: Overall burden and rates of treatment and control. Arch Intern Med,vol.166 pp.1884– 1891,2006 Abstract/FREE Full Text
[7] P. Muntner, LL .Hamm, JW. Kusek, J .Chen, PK. Whelton, J. He: The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med,vol.140 pp.9– 17,2004Abstract/FREE Full Text
[8] J. Chen, P .Muntner, LL .Hamm, DW .Jones, V. Batuman, V. Fonseca, PK .Whelton, J .He: The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Medvol.140 pp.167– 174,2004 Abstract/FREE Full Text
[9] DJ. Maron, SM. Grundy, PM. Ridker, TA. Pearson. Dyslipidemia, other risk factors, and the prevention of coronary heart disease. In: Fuster V, Alexander RW, O'Rourke RA, Roberts R, King SB, Prystowsky EN, et al, editors. Hurst's the heart. 11th ed. New York: McGraw-Hill; 2004. pp. 1093-122.
[10] A.. Tuğrul. Diabetes mellitus ve hipertansiyon. Trakya Univ Tip Fak Derg 2002 vol.19 pp .44-54.
[11] A. Tuğrul. Diabetes mellitus ve aterosklerotik komplikasyonlar. Trakya Univ Tip Fak Derg 1994vol.11pp.305-11.
[12] Gröne H. J., Hohbach J., Gröne E. F. (1996) Modulation of glomerular sclerosis and interstitial fibrosis by native and modified lipoproteins. Kidney Int. Suppl. 54:S18–S22.Medline
[13] R Risdon. A., J. C. Sloper, H. E De WardenerRelationship between renal function and histological changes found in renal biopsy specimens from patients with persistent glomerular nephritis. Lancet,(1968) vol. 2pp.363–366.Medline
[14] S. Mackensen-Haen, R. Bader, K. E. Grund, A. Bohle Correlations between renal cortical interstitial fibrosis, atrophy of the proximal tubules and impairment of the glomerular filtration rate. Clin. Nephrol. (1981)vol. 15pp.167–171.Medline
[15] A. A Eddy Interstitial fibrosis in hypercholesterolemic rats: role of oxidation, matrix synthesis, and proteolytic cascades. Kidney Int. .(1998)vol. 53pp.1182–1189.CrossRefMedline
[16] LL Stoll, Denning GM, Weintraub NL. Potential role of endotoxin as a proinflammatory mediator of atherosclerosis.Arterioscler Thromb Vasc Biol 2004vol. 24pp. 2227–36.
[17] HD Paik, JS Park, E Park. Effects of Bacillus polyfermenticus SCD on lipid and antioxidant metabolism in rats fed a high fat and high cholesterol diet. Biol Pharm Bull 2005vol. 28pp.1270-4.
[18] Y. Kerttuala, M. Vaara, L. Pyhala, H. Sariola, E. Kostiainen, JK. Huttunen. Effect of bacterial lipopolysaccharide on serum lipids and on the development of aortic atherosclerosis in rabbits. Atherosclerosis 1986vol. 59pp. 307-12.
[19] S. Yla- Herttluala, E. Pesonen, E .Kaprio, J Rapola, T. Soveri, J. Viikari, E. Savilahti, et. al. Effect of repeated endotoxin treatment and hypercholesterolemia on preatherosclerotic lesions in weaned pigs. II. Lipid and glycosaminoglycan analysis of intima and inner media. Atherosclerosis 1988vol. 72pp. 173-81.
[20] HA Lehr, TA Sagban, C Ihling, U Zähringer, KD Hungerer, M Blumrich, K Reifenberg, S Bhakdi. Immunopathogenesis of atherosclerosis: endotoxin accelerates atherosclerosis in rabbits on hypercholesterolemic diet. Circulation 2001vol. 104pp. 914-20.
[21] T. Fukai, ZS Galis, X Meng, S Parthasarathy, DG Harrison. Vascular expression of extracellular superoxide dismutase in atherosclerosis. J Clin Invest, 1998vol. 101pp.2101-11.
[22] M. S. Ahmed and M .Y Olfat Physiological Studies on the Risk Factors Responsible for Atherosclerosis in Rats. Nature and Science, 2010vol. 8 no.5pp.144-151
[23] HJ. Gröne, AK. Walli, EF. Gröne, P. Niedmann, JT .Thiery, D. Seidel, U. Helmchen. Induction of glomerulosclerosis by dietary lipids. A functional and morphologic study in the rat. Laboratory Investigation, 1989; vol.no.11pp. 433-46
[24] NT Nguyen, E Varela, A Sabio, CL Tran, M Stamos, SE Wilson. Resolution of hyperlipidemia after laparoscopic Roux-en-Y gastric bypass. J Am Coll Surg, 2006vol.203pp.24-9.
[25] J. Sano, S. Shirakura, S. Oda, T .Hara, T. Ishihara. Foam cells generated by a combination of hyperglycemia and hyperlipemia in rats. Pathol Int, 2004vol.54pp.904-13.
[26] AM Wolf, B Busch, HW Kuhlmann, U Beisiegel. Histological changes in the liver of morbidly obese patients: correlation with metabolic parameters. Obes Surg ,2005vol15pp.228-37.
[27] Max W.and Martin B.. Electron Microscopy of Renal Coagulative Necrosis Due to dl-Serine, with Special Reference to Mitochondrial Pyknosis. Am J Pathol. 1964 vol.44no.3pp.383–400.
[28],M. Cook., ,J Osvaldo., and, H Latta.()Changes in renal glomeruli during autolysis.Lab Invest. 1965vol.,14pp.623.
[29] SQ. Alam, SM .Abdel-Hakim, BS Alam, IY Ibrahim. Effect of essential fatty acid deficiency on G-proteins, cAMP-dependent protein kinase activity and mucin secretion in the rat submandibular salivary glands. Cell Signal 1995vol.7pp.773-81.
[30] SQ Alam, YF Ren, BS Alam. Effect of cholesterol feeding on membrane fluidity, (Na+ + K+) ATPase, adenylate cyclase, [3H]-ouabain-, and [3H]-dihydroalprenolol-binding in rat submandibular salivary glands. J Dent Res 1987vol.66pp.605-7.
[31] H. Nakagawa, N. Tsunooka, Y. Yamamoto, M .Yoshida, T. Nakata, K .Kawachi. Pitavastatin prevents intestinal ischemia/reperfusion-induced bacterial translocation and lung injury in atherosclerotic rats with hypoadiponectinemia. Surgery 2009,vol.145no.5pp. 542-49.
[32] Y Wu, J Li, J Wang, Q Si, J Zhang, Y Jiang, L Chu. Anti-atherogenic effects of centipede acidic protein in rats fed an atherogenic diet. Journal of Ethnopharmacology 2009, vol. 122no.3pp.509-16.
[33] E .Cecchi, R. Marcucci, D. Poli, E. Antonucci, R. Abbate, GF .Gensini, D. Prisco, L. Mannini. Hyperviscosity as a possible risk factor for cerebral ischemic complications in atrial fibrillation patients. American Journal of Cardiology 2006,vol. 97no.12pp. 1745-48.
[34] R. Collins, J. Armitage, S. Parish, P. Sleight, R. Peto. Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet, 2004, vol.363pp. 757-67.
[35] S. Delbosc, M. Morena, F Djouad, C Ledoucen, B Descomps, JP Cristol. Statins, 3- hydroxy-3-methylglutaryl coenzyme Areductase inhibitors, are able to reduce superoxide anion production by NADPH oxidase in THP-1-derived monocytes. Journal of Cardiovascular Pharmacology 2002, vol.40no.4pp. 611-17.
[36], H .Ando., Y. Nishio, K. Ito, A. Nakao, L. Wang, Y. L. Zhao, K. Kitaichi, K. Takagi, and T. Hasegawa.. Effect of endotoxin on P-glycoprotein-mediated biliary and renal excretion of rhodamine 123 in rats. Antimicrob. Agents Chemother2001vol.. 45pp.3462-3467.Abstract/FREE Full Text↵
[37] S. E. Richardson,, M. A. Karmali, L. E. Becker, and C. R. Smith.. The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infections. Hum. Pathol1988,vol. 19pp.1102-1108.CrossRefMedline↵
[38] M Nadai,., T. Hasegawa, L. Wang, S. Haghgoo, T. Okasaka, T. Nabeshima, and N. Kato.. Alterations in renal uptake kinetics of the xanthine derivative enprofylline in endotoxaemic mice. J. Pharm. Pharmacol1996,vol. 48pp.744-748.Medline↵
[39], L. Wang, T. Hasegawa, N. Nadai, I. Muraoka, T. Nabeshima, and N. Kato.. The effect of lipopolysaccharide on the disposition of xanthines in rats. J. Pharm. Pharmacol1993,vol. 45pp.34-38.Medline
[40] SJD Brooks, JM Lyons, AI Braude, Immunization against retrograde pyelonephritis. I. Production of an experimental model of severe ascending Escherichia coli pyelonephritis without bacteremia in rats. Am J Pathol, 1974vol.74pp.345-58.MedlineWeb of Science
[41],D. Ponraj. and P. Gopalakrishakone.Renal lesion in rhabdomyolysis caused by Pesedoechis australis snake myotoxin.Kidney Int., 1994,vol51pp.1956-1969.
[42], G. CORITSIDIS, , V. RIFICI, , S GUPTA, et al: Preferential binding of oxidized LDL to rat glomeruli in vivo and cultured mesangial cells in vitro. Kidney Int ,1991vol 39pp. 858–866, | PubMed | ISI | ChemPort |
[43], J .WASSERMAN, , A. SANTIAGO, , V .RIFICI, et al: Interactions of low density lipoprotein with rat mesangial cells. Kidney Int, 1989,vol. 35pp. 1168–1174, | PubMed | ISI | ChemPort |
[44], Y. NISHIDA, , H. ODA, , N. YORIOKA: Effect of lipoproteins on mesangial cell proliferation. Kidney Int ,1999 vol.56no. 71pp.S51–S53, | Article | ISI |
[45], SB KIM, , SA KANG, , YJ CHO, et al: Effects of low density lipoprotein on type IV collagen production by cultured rat mesangial cells. Nephron ,1994,vol. 67pp. 327–333, | PubMed |
[46], S. LAVAUD, , O. MICHEL, , C .SASSY-PRIGENT, et al: Early influx of glomerular macrophages precedes glomerulosclerosis in the obese Zucker rat model. J Am Soc Nephrol ,1996,vol 7pp. 2604–2615, | PubMed | ISI | ChemPort |
[47] I. PESEK-DIAMOND, , G DING, , J, FRYE et al: Macrophages mediate adverse effects of cholesterol feeding in experimental nephrosis. Am J Physiol .1992vol. 263pp. F776–F783, | PubMed | ChemPort |
[48] S. MATSUDA, , T .ARAI, , K. IWATA, et al: A high-fat diet aggravates tubulointerstitial but not glomerular lesions in obese Zucker rats. Kidney Int. 1999,vol.. 56 no 71pp.S150–S152, | Article |
[49] T. Suto, G. Losonczy, C. Qiu, et a.lAcute changes in urinary excretion of nitrite + nitrate do not necessarily predict renal vascular NO production. Kidney Int. 1995,vol.48pp.1272-7.MedlineWeb of Science
Improving Interdisciplinary Collaboration Regarding End-of-Life Decisions: a Pilot Study
Author(s) Hanne I. Jensen, Jette Ammentorp and Helle Ording
Abstract

The aim was to examine healthcare professionals’ evaluation of interdisciplinary audits as a method to improve interdisciplinary collaboration regarding end-of-life decision-making. Three interdisciplinary audits were conducted with participation of 8 primary physicians, 9 intensivists and 12 nurses. The participants were first asked to assess real-life cases, and subsequently, based on the cases, to discuss current practice of end-of-life decision-making. Form and profit of the audits were evaluated by a short questionnaire at the end of the sessions and three months later. Evaluated immediately after and three months after audit most participants (97% and 89%, respectively) found that this type of audit to great or some extent was usable to improve interdisciplinary collaboration regarding end-of-life decision-making. All emphasised the interdisciplinarity as one of the benefits of the discussions. After three months 35% - 45% found that collaboration and own practice to some or less extent had changed after the audit. The study suggests that healthcare professionals experience audit as a usable method to improve interdisciplinary collaboration regarding end-of-life decision-making in the ICU.



References
[1] S. Cohen, C. Sprung, P. Sjokvist, A. Lippert, B. Ricou, M. Baras et al., “Communication of end-of-life decisions in European intensive care units,” Intensive Care Med, vol.31, no. 9, pp. 1215-1221, Sep. 2005.
[2] M. C. Poncet, P. Toullic, L. Papazian, N. Kentish-Barnes, J. F. Timsit, F. Pochard et al., “Burnout syndrome in critical care nursing staff,” Am J Respir Crit Care, vol. 175, no. 7, pp. 698-704, Apr. 2007.
[3] K. Halvorsen, R. Forde and P. Norvedt, ”Value choices and considerations when limiting intensive care treatment: a qualitative study,” Acta Anaesthesiol Scand, vol. 53, no. 1, pp. 10-17, Jan. 2009.
[4] M. Heland, “Fruitful or futile: intensive care nurses’ experiences and perceptions of medical futility,” Aust Crit Care, vol. 19, no. 1, pp. 25-31, Feb. 2006.
[5] J. Cassell, T. G. Buchman, S. Streat and R. M. Stewart, “Surgeons, intensivists, and the covenant of care: administrative models and values affecting care at the end of life,” Crit Care Med, vol. 31, no. 5, pp. 1551-1557, May 2003.
[6] C. L. Sprung, S. L. Cohen, P. Sjokvist, M. Baras, H. H. Bulow, S. Hovilehto et al., “End-of-life practices in European intensive care units: the Ethicus Study,” JAMA, vol. 290, no. 6, pp. 790-797, Aug. 2003.
[7] C. L. Sprung, P. Maia, H. H. Bulow, B. Ricou, A. Armaganidis, M. Baras et al, “The importance of religious affiliation and culture on end-of-life decisions in European intensive care units,” Intensive Care Med, vol. 33, no. 10, pp. 1732-1739, Oct. 2007.
[8] H. H. Bulow, C. L. Sprung, K. Reinhart, S. Prayag, B. Du, A. Armaganidis et al., “The world’s major religious’ points of view on end-of-life decisions in the intensive care unit,” Intensive Care Med, vol. 34, no. 3, pp. 423-430, Mar. 2008.
[9] J. R. Curtis and J. L. Vincent, “Ethics and end-of-life care for adults in the intensive care unit”, Lancet, vol. 376, no. 9749, pp. 1347-1353, Oct. 2010.
[10] E. Ferrand, F. Lemaire, B. Regnier, K. Kuteifan, M. Badet, P. Asfar et al., “Discrepancies between perceptions by physicians and nursing staff of intensive care unit end-of-life decisions, “ Am J Respir Crit Care, vol. 167, no. 10, pp. 1310-1315, May 2003.
[11] C. M. Breen, A. P. Abernethy, K. H. Abbott and J. A. Tulsky, “Conflict associated with decisions to limit life-sustaining treatment in intensive care units,” J Gen Intern Med, vol. 16, no. 5, pp. 283-289, May 2001.
[12] J. G. Baggs, “Development of an instrument to measure collaboration and satisfaction about care decisions,” J Adv Nurs, vol. 20, no. 1, pp. 176-182, Jul. 1994.
[13] T. E. Weaver, “Enhanching multiple disciplinary teamwork,” Nurs Outlook, vol. 56, no. 3, pp. 108-114, May. 2008.
[14] C. M. Lilly, L. A. Sonna, K. J. Haley and A F. Massaro, “Intensive communication: four-year follow-up from a clinical practice study,” Crit Care Med, vol. 31, no. 5 Suppl, pp. S394-S399, May 2003.
[15] K. A. Puntillo and J. L. McAdam, “Communication between physicians and nurses as a target for improving end-of-life care in the intensive care unit: challenges and opportunities for moving forward,” Crit Care Med, vol. 34, no. 11 Suppl, pp. S332-S340, Nov. 2006.
[16] E. Azoulay, J. F. Timsit, C. L. Sprung, M. Soares, K. Rusinova, A. Lafabrie et al., “Prevalence and factors of intensive care conflicts: the conflicus study,” Am J Respir Crit Care, vol. 180, no. 9, pp. 853-860, Nov. 2009.
[17] H. I. Jensen, J. Ammentorp, M. Erlandsen and H. Ørding, “Withholding or withdrawing therapy in intensive care units: an analysis of collaboration among healthcare professionals,” Intensive Care Med, vol. 37, no. 10, pp. 1696-1705, Oct. 2011.
[18] R. McSherry and P. Pearce, “Clinical Governance. A guide to Implementation for Healthcare Professionals,” Third ed., 2011.
[19] M. Zwarenstein, J. Goldman and S. Reeves, “Interprofessional collaboration: effects of practice-based interventions on professional practice and healthcare outcomes,“ Cochrane Database Syst Rev, no. 3, CD000072, 2009.
[20] H. I. Jensen, J. Ammentorp and P. E. Kofoed, “User satisfaction is influenced by the interval between a health care service and the assessment of the service,” Soc Sci Med, vol. 70, no. 12, pp. 1882-1887, Jun. 2010.
[21] G. Jamtvedt, J. M. Young, D. T. Kristoffersen, M. A. O’Brian and A. D. Oxman, ”Audit and feedback: effects on professional practice and health care outcomes,” Cochrane Database Syst Rev, no. 2, CD000259, 2006.
[22] R. J. Jox, M. Krebs, M. Fegg, S. Reiter-Theil, L. Frey, W. Eisenmenger et al., “Limiting life-sustaining treatment in Germen intensive care units: a multiprofessional survey,“ J Crit Care, vol. 25, no. 3, pp. 413-419, Sep. 2010.
[23] V. Bach, J. Ploeg and M. Black, “Nursing Roles in End-of-Life Decision Making in Critical Care Settings,” West J Nurs Res, vol. 31, no. 4, pp. 496-512, Jun. 2009.
Neridronic Acid Effects on Postmenopausal Osteoporosis: Treat and Adhere Anyways
Author(s) A.Lurati, D.Bompane, K.Re, MG Marrazza and M Scarpellini
Abstract

Osteoporosis is a major health concern that is associated with an increased risk of first and subsequent bone fractures. Untreated osteoporosis results in considerable morbidity. Currently, bisphosphonates are the mainstay of treatment for osteoporosis and the aim of this study was to assess the effects of intravenous (IV) and intramuscular (IM) neridronate (NE) on femoral/lumbar bone mineral density (BMD) and to fracture the risk in patients with postmenopausal osteoporosis. Data were collected on age, weight, body mass index, physical activity, smoking, height loss, history of falls, total hip and lumbar BMD, and creatinine clearance. Inclusion criteria were a lumbar or femoral BMD T score < 2.5; Exclusion criteria were secondary osteoporosis, previous osteoporotic fracture, prior bisphosphonates or osteoporosis medications other than calcium or colecalciferol, presence of any concomitant skeletal metabolic disease.

METHODS: 164 patients (mean age 64±2.7 years) with postmenopausal osteoporosis confirmed with a lumbar and femoral DEXA BMD scan received NE IV 100mg every 8 weeks for 18 months and subsequently IM NE 25 mg every 4 weeks for 18 months. All patients had gastric or esophageal conditions that contraindicated treatment with oral bisphosphonates (BPs). All subjects received daily calcium 1 g and vitamin D 800 UI. Lumbar and femoral DEXA BMD scans were performed at baseline, 18 months and 36 months.


RESULTS: After 18 months of IV therapy mean ±SD lumbar BMD was significantly increased (baseline -2.8±1.2 vs 18 months -2.6±1.4; p<0.01). Mean ±SD femoral neck BMD was also improved (baseline -2.15±1.1 vs 18 months -2.01±0.5; p<0.05). After an additional 18 months of IM NE the mean ±SD BMD values were lumbar -1.89±0.8 and femur -1.49±1.48; p< 0.01 vs. baseline.


CONCLUSION: The results of this study confirm the role of NE in the treatment of postmenopausal osteoporosis and indicate the potential usefulness of intramuscular administration in the treatment of these patients.



References
[1] Reginster JY, Burlet N. Osteoporosis: a still increasing prevalence. Bone. 2006; 38(2 Suppl 1):54-59.
[2] Rotella DP. Osteoporosis: challenges and new opportunities for therapy. Curr Opin Drug Discov Devel. 2002; 5:477-486.
[3] Bonura F. Prevention, screening, and management of osteoporosis: an overview of the current strategies. Postgrad Med. 2009; 121:5-17.
[4] Prevention and management of osteoporosis. World Health Organ Tech Rep Ser. 2003; 921:1-164.
[5] Kanis JA, Oden A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int. 2007; 18:1033-1046.
[6] Kanis J. FRAXTM WHO fracture risk assessment tool. http://wwwshefacuk/FRAX/ index htm. Accessed September 15, 2009.
[7] Russell RG. Bisphosphonates: the first 40 years. Bone. 2011;49:2-19
[8] Adami S, Bevilacqua M, Broggini M, et al. Short-term intravenous therapy with Neridronate in Paget's disease. Clin Exp Rheumatol. 2002; 20:55-58.
[9] Braga V, Gatti D, Colapietro F, et al. Intravenous intermittent neridronate in the treatment of postmenopausal osteoporosis. Bone. 2003; 33:342-345.
[10] Graham DY, Malaty HM, Goodgame R. Primary amino-bisphosphonates: a new class of gastrotoxic drugs-comparison of alendronate and aspirin. Am J Gastroenterol.1997;92(8):1322–1325.
[11] Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone. 1996;18(2):75–85.
[12] Miller PD. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy. Clin Ther. 2005 Apr; 27(4): 361-376.
[13] Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther. 2006; 28: 236-242.
[14] Miller NH. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med. 1997; 102:43-49.
[15] Porras AG, Holland SD, Gertz BJ. Pharmacokinetics of alendronate. Clin Pharmacokinet. 1999; 36:315-328.
[16] Russell RG. Bisphosphonates: from bench to bedside. Ann N Y Acad Sci. 2006; 1068: 367-401.
[17] Nancollas GH, Tang R, Phipps RJ, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006; 38:617-627.
[18] Adami S, Gatti D, Bertoldo F, et al. Intramuscular neridronate in postmenopausal women with low bone mineral density. Calcif Tissue Int. 2008; 83:301-307.
[19] Rizzoli R, Reginster JY, Boonen S, et al. Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int. 2011;89:91-104.
[20] Merlotti D, Rendina D, Gennari L, et al. Comparison of intravenous and intramuscular neridronate regimens for the treatment of Paget disease of bone. J Bone Miner Res. 2011;26:512-518.
The Anti-oxidant Activities and the Best Therapeutic Time Window and Dose of Picroside II in Cerebral Ischemic Injury in Rats
Author(s) Ji Xiao-jun, Chang Cui-cui, Lin Rong-hai, Zhang Rui and Zhao Li
Abstract

The aim is to optimize the anti-oxidant effect and the therapeutic dose and time window of picroside II by orthogonal test in cerebral ischemic injury in rats. The forebrain ischemia models were established by bilateral common carotid artery occlusion (BCCAO) methods. The successful models were randomly grouped according to orthogonal experimental design and treated by injecting picroside II intraperitoneally at different ischemic time with different dose. The activities of superoxide dismutase (SOD), glutathione peroxidase (GSHPx) and catalase (CAT) in serum and brain tissue were respectively determined by xanthinoxidase method, chemical colorimetry and chemiluminescence immunoassay. The optimized composition of the therapeutic dose and time window of picroside II in cerebral ischemic injury were (1) ischemia 1.5h with 20mg/kg, 1.5h with 10mg/kg and 1.5h with 20mg/kg body weight according to the activities of SOD, GSHPx and CAT in serum, (2) ischemia 1.5h with 20mg/kg, 2.0h with 20mg/kg and 1.5h with 10mg/kg body weight according to the activities of SOD, GSHPx and CAT in brain tissue. Combined evaluation from the principle of lowest therapeutic dose with longest time window, the optimized composition of the therapeutic dose and time window of picroside II in cerebral ischemic injury is 10-20mg/kg body weight at ischemia 1.5-2.0h.



References
[1]Shibata N, Kobayashi M. The role for oxidative stress in neurodegenerative diseases. Brain Nerve 2008;60:157-170.
[2]Li M, Zhao J, Hu Y, et al. Oxygen free radicals regulate energy metabolism via AMPK pathway following cerebral ischemia. Neurol Res 2010;32:779-784.
[3]Tomatsuri N, Yoshida N, Takagi T, et al. Edavavone, a newly developed radical scavenger protects against ischemia-reperfusion injury of the small intestine in rats. Int J Mol Med 2004;13:105-107.
[4]Gargouri B, Mansour RB, Abdallah FB, et al. Protective effect of quercetin against oxidative stress caused by dimethoate in human peripheral blood lymphocytes. Lipids Health Dis 2011;10:149-152.
[5]Yan TH, Jia Y, Yang W, et al. Protective effects of on focal cerebral ischemic-reperfusion injury in rats. Chin Pharmacol Bull 2008;24:1521-1524.
[6]Wang JY, Yu R, Yao MH. Protective effects and mechanisms of salidroside on cerebral ischemia-reperfusion injury. Chin J TCM Pharm 2010; 25:456-459.
[7]Chen X, Yang YJ, Tao YG, et al. Endogenous protective effects of antioxidant enzymes on infectious brain injury in rats. Chin Neurol 2000;33:90-92.
[8]Li P, Matsunaga K, Yamakuni T, et al. Picrosides I and II selective enhancers of the mitogen-activated protein kinase-dependent signaling pathway in the action of neuritogenic substances on PC12D cells. Life Sci 2002;71:1821-1835.
[9]Tao YW, Liu JW, Wei DZ, et al. Protective effect of picroside II on the damage of cultured PC12 cells in vitro. Chin J Clin Pharmacol Therap 2003;8:27-30.
[10]Guo MC, Cao Y, Liu JW. Protective effects of picroside II on glutamate injury of PC12 cells. Chin J Clin Pharmacol Therap 2007;12:440-443.
[11]Li Z, Li Q, Guo YL, et al. Interference effect of picroside II on cerebral ischemia reperfusion injury in rats. Acta Anat Sinica 2010;41:9-12.
[12]Sun L, Li XD, Wang L, et al. The Anti-oxidant effect and the possible mechanism of picroside II in cerebral ischemia reperfusion injury in rats. Neural Regen Res 2011;6:1141-1146.
[13]Li Q, Li Z, Xu XY, et al. Neuroprotective properties of picroside II in rat model of focal cerebral ischemia. Int J Mol Sci 2010;11:4580-4590.
[14]Pei HT, Su X, Zhao L, et al. Primary study for the therapeutic dose and Time window of picroside II in treating cerebral ischemic injury in rats. Int J Mol Sci 2012;13:2551-2562.
[15]Márquez-Martín A, Jiménez-Altayó F, Dantas AP, et al. Middle cerebral artery alterations in a rat chronic hypoperfusion model. J Appl Physiol 2012;112:511-518.
[16] Long SH, Yu ZQ, Shuai L, et al. The hypoglycemic effect of the kelp on diabetes mellitus model induced by alloxan in rats. Int J Mol Sci, 2012, 13(3):3354-3365.
[17]Gu W, Fan XJ, Wu J, et al. Protective effect of Picroside II against H2O2-induced damage in L-02 cells. World Chin J Digestol 2008;16:3274-3278.
[18]Li DL, Wang XY, Han H, et al. Effect of progesterone on the activity of SOD and GSH-PX in brain tissue with hypoxic-ischemic encephalopathy in new born rats. Chin Pharmcol Bull 2007;23:276-277.
[19]Moralí G, Letechipía-Vallejo G, López-Loeza E, et al. Post ischemic administration of progesterone in rats exerts neuroprotective effects on the hippocampus. Neurosci Lett 2005;382:286-290.
[20]Chen HB, Chen TP, Hou GF, et al. Neuroprotection of progesterone against cerebral ischemia-reperfusion injury on rats and the effect on IP3 content. Acta Universitatis Medicinalis Anhui 2012;47:511-512.
[21]Lin Y, Cui HY, Zhao XM, et al. Protective Effect of Ginkgolide B against cerebral ischemia-reperfusion injury on rats. Chin J Pharmacol Toxicol 2012;26:430-431.
[22]Zhang XT, Liang J, Liu HX, et al. Protective Effects of Ginkgolide N on Focal Cerebral Ischemia Reperfusion Injury in Rats. Chin J Exp Tradit Med Formulae 2012; 18:141-144.
[23]Guo C, Tong L, Xi M, et al. Neuroprotective effect of calycosin on cerebral ischemia and reperfusion injury in rats. J Ethnopharmacol 2012;144:768-774.
[24]Sun YX, Tang Y, Wu AL, et al. Neuroprotective effect of liquiritin against focal cerebral ischemia/ reperfusion in mice via its antioxidant and antiapoptosis properties. J Asian Nat Prod Res 2010;12:1051-1060.
[25]Li C, Zhang DS, Zhao XQ, et al. Experimental screening study of three chrysophanol formulations on learning and memory function of mice with cerebral ischemia reperfusion. Chin Pharmacol Bull 2010;26:1607-1612.
[26]Wang S, Zhang DS, Xue GP, et al. Effects of chrysophanol on H2O2 and CAT in cerebrum of mice induced by cerebral ischemia reperfusion injury. Pharmacol Clin Chin Materia Medica 2008;24:22-24.
[27] Wang S, Zhang DS, Zhang L, et al. Effects of emodin on H2O2 and CAT in cerebrum of mice induced by cerebral ischemia reperfusion injury. Chin J Pharmacol Toxicol 2012; 26:417.
[28] Li P, Matsunaga K, Yamakuni T, et al. Potentiation of nerve growth factor-action by picrosides I & II, natural iridoids, in PC12 cells. Eur J Pharmacol 2000;406:203-208.
[29]Zhao DM, Zhang ZQ, Duan YX, et al. Neuroprotective effect of picroside II on cerebral ischemia-reperfusion injury in rats. J Interl Pharmaceut Res 2010;37:461-468.